We will find out soon what caused today's move, imo. Only catalyst in Q3 is the FDA meeting on phase 2 Ovarian. I don't think that was the cause of today's move because the data has been published. Perhaps the phase 2 went well and VB-111 received fast track designation for ovarian?
The company is also actively looking for partners for its NASH products so that can happen at any time.
News 
Market Data 
Discover 
AI
